Ludovico Abenavoli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5230211/publications.pdf

Version: 2024-02-01

279 papers

8,637 citations

66343 42 h-index 82 g-index

284 all docs

284 docs citations

times ranked

284

10585 citing authors

#	Article	IF	Citations
1	Triglyceride-Glucose Index and Hepatic Steatosis Index for the assessment of liver steatosis in HCV patients. Minerva Gastroenterology, 2023, 69, .	0.5	3
2	Gut microbiota and non-alcoholic fatty liver disease. Minerva Gastroenterology, 2022, 67, .	0.5	10
3	Microbiome in Critical Care: An Unconventional and Unknown Ally. Current Medicinal Chemistry, 2022, 29, 3179-3188.	2.4	13
4	The Gut Microbiota Changes in Obese People: A New Perspective for the Modern Medicine. The International Journal of Gastroenterology and Hepatology Diseases, 2022, 1 , .	0.2	0
5	Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation. Medicina (Lithuania), 2022, 58, 84.	2.0	21
6	Gut microbiota and cardiovascular diseases axis. Minerva Medica, 2022, 113, .	0.9	9
7	Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed. Minerva Gastroenterology, 2022, 67, 357-368.	0.5	5
8	The role of gut microbiota in gastrointestinal diseases: the heart of the matter. Minerva Gastroenterology, 2022, 67, 312-313.	0.5	3
9	Effect of Whey Proteins on Malnutrition and Extubating Time of Critically III COVID-19 Patients. Nutrients, 2022, 14, 437.	4.1	6
10	Akkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders. Minerva Endocrinology, 2022, 47, .	1.1	14
11	The paradigm shift from <scp>NAFLD</scp> to <scp>MAFLD</scp> : A global primary care viewpoint. Liver International, 2022, 42, 1259-1267.	3.9	15
12	Evaluation of serum calprotectin as novel biomarker in psoriatic patients: a prospective pilot study. Minerva Medica, 2022, 113 , .	0.9	2
13	Biological Mechanisms behind Wischnewsky Spots Finding on Gastric Mucosa: Autopsy Cases and Literature Review. International Journal of Environmental Research and Public Health, 2022, 19, 3601.	2.6	4
14	Phenotypic Variability in Phelan–McDermid Syndrome and Its Putative Link to Environmental Factors. Genes, 2022, 13, 528.	2.4	5
15	From Pre- and Probiotics to Post-Biotics: A Narrative Review. International Journal of Environmental Research and Public Health, 2022, 19, 37.	2.6	35
16	Liver injury associated with high value of D-dimer plasmatic level in COVID-19 patients. Minerva Gastroenterology, 2022, , .	0.5	3
17	Treatment with phosphatidylcholine of patients with nonalcoholic fatty liver disease: a prospective pilot study. Minerva Gastroenterology, 2022, 68, .	0.5	2
18	Mediterranean Diet: The Beneficial Effects of Lycopene in Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2022, 11, 3477.	2.4	11

#	Article	IF	CITATIONS
19	Measuring Mood and Anxiety Disorders by Patient Reported Outcomes in Inflammatory Bowel Disease: A Literature Review Update. Reviews on Recent Clinical Trials, 2022, 17, 156-170.	0.8	3
20	Predicting the Spread of SARS-CoV-2 in Italian Regions: The Calabria Case Study, February 2020–March 2022. Diseases (Basel, Switzerland), 2022, 10, 38.	2.5	8
21	Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota. Metabolites, 2022, 12, 647.	2.9	20
22	Sudden olfactory loss as an early marker of COVID-19: a nationwide Italian survey. European Archives of Oto-Rhino-Laryngology, 2021, 278, 247-255.	1.6	15
23	Liver Cirrhosis Complications Management at the Emergency Department. Reviews on Recent Clinical Trials, 2021, 15, 331-338.	0.8	3
24	Next generation of strain specific probiotics in diabetes treatment: the case of Prevotella copri. Minerva Endocrinologica, 2021, 45, 277-279.	1.8	6
25	Management of functional dyspepsia in 2020: a clinical point of view. Minerva Gastroenterologica E Dietologica, 2021, 66, 331-342.	2.2	11
26	Risk Management and Treatment of Coagulation Disorders Related to COVID-19 Infection. International Journal of Environmental Research and Public Health, 2021, 18, 1268.	2.6	40
27	Nutrition and COVID-19 pandemic: the case of Mediterranean diet. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2021, 179, .	0.1	1
28	Metabolic Benefits of Probiotic Combination with Absorbent Smectite in type 2 Diabetes Patients a Randomised Controlled Trial. Reviews on Recent Clinical Trials, 2021, 16, 109-119.	0.8	11
29	Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. Nutrients, 2021, 13, 494.	4.1	70
30	Preface. Reviews on Recent Clinical Trials, 2021, 16, 2-2.	0.8	0
31	Anxiety and Gastrointestinal Symptoms Related to COVID-19 during Italian Lockdown. Journal of Clinical Medicine, 2021, 10, 1221.	2.4	13
32	Potential role of fecal gluten immunogenic peptides to assess dietary compliance in celiac patients. Minerva Gastroenterology, 2021, 67, .	0.5	0
33	From gut to skin: the association between celiac disease and cutaneous abnormalities. Minerva Gastroenterology, 2021, , .	0.5	2
34	Nutritional Status and the Critically Ill Patient: Gut Microbiota and Immuno-Nutrition in I.C.U. at the Time of SARS-COV 2 Pandemic. Gastroenterology Insights, 2021, 12, 259-269.	1.2	1
35	Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives. Nutrients, 2021, 13, 1679.	4.1	14
36	The combination of chondroitin sulfate and probiotic prevents oxidative stress in the serum of rats with experimental osteoarthritis. Minerva Biotechnology and Biomolecular Research, 2021, 33, .	0.5	3

#	Article	IF	CITATIONS
37	Probiotics and gut health. Minerva Gastroenterology, 2021, , .	0.5	4
38	New Strategies for Clinical Trials in Autism Spectrum Disorder. Reviews on Recent Clinical Trials, 2021, 16, 131-137.	0.8	1
39	Genetic and environmental factors influencing the interaction between the gut microbiota and the human host: implications for gastrointestinal disorders and treatment approaches. Minerva Gastroenterology, 2021, , .	0.5	1
40	Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review. Reviews on Recent Clinical Trials, 2021, 16, 138-145.	0.8	18
41	Non-alcoholic fatty liver disease and cardiovascular disease: a close relationship. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 183-184.	0.9	1
42	Are probiotics effective in reversing non-alcoholic steatohepatitis?. Hepatobiliary Surgery and Nutrition, 2021, 10, 407-409.	1.5	0
43	Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series. Medicine and Pharmacy Reports, 2021, 94, 289-297.	0.4	4
44	Intravenous Magnesium – Lidocaine - Ketorolac Cocktail for Postoperative Opioid Resistant Pain: A Case Series of Novel Rescue Therapy. Reviews on Recent Clinical Trials, 2021, 16, 288-293.	0.8	1
45	Mediterranean diet and NAFLD: where are we now?. Minerva Endocrinology, 2021, , .	1.1	4
46	Probiotic Bacterial Application in Pediatric Critical Illness as Coadjuvants of Therapy. Medicina (Lithuania), 2021, 57, 781.	2.0	1
47	Management of Leaks Following Laparoscopic Sleeve Gastrectomy Using Specifically Designed Large Covered Metal Stents. Reviews on Recent Clinical Trials, 2021, 16, 303-308.	0.8	0
48	Effectiveness and Safety of A Nutraceutical Formulation for the Treatment of Functional Dyspepsia in Primary Care. Reviews on Recent Clinical Trials, 2021, 16, 329-334.	0.8	2
49	Lock, Stock and Barrel: Role of Renin-Angiotensin-Aldosterone System in Coronavirus Disease 2019. Cells, 2021, 10, 1752.	4.1	12
50	Current Strategies to Minimize Ischemia-Reperfusion Injury in Liver Transplantation: A Systematic Review. Reviews on Recent Clinical Trials, 2021, 16, 372-380.	0.8	5
51	SARS-CoV-2 Spread Dynamics in Italy: The Calabria Experience. Reviews on Recent Clinical Trials, 2021, 16, 309-315.	0.8	6
52	Analysis of the persistence time of the SARS-CoV-2 virus in the cadaver and the risk of passing infection to autopsy staff. Medico-Legal Journal, 2021, 89, 40-53.	0.5	11
53	Ancient wheats: beneficial effects on insulin resistance. Minerva Medica, 2021, 112, 641-650.	0.9	20
54	Noninvasive biomarkers in predicting nonalcoholic steatohepatitis and assessing liver fibrosis: systematic review and meta-analysis. Panminerva Medica, 2021, 63, .	0.8	22

#	Article	IF	Citations
55	Parkinsonism and corticospinal tracts involvement in hepatic encephalopathy. Journal of the Neurological Sciences, 2021, 429, 118611.	0.6	0
56	Crohn disease. Nurse Practitioner, 2021, 46, 22-30.	0.3	3
57	The limits of diagnosis of testicular torsion in the child: Medicolegal implications in clinical practice. Clinical Case Reports (discontinued), 2021, 9, e05180.	0.5	2
58	Potential role of fecal gluten immunogenic peptides to assess dietary compliance in celiac patients. Minerva Gastroenterology, 2021, 67, 69-71.	0.5	0
59	The role of gluten-free diet in nonalcoholic fatty liver disease development. European Review for Medical and Pharmacological Sciences, 2021, 25, 6613-6618.	0.7	1
60	Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study. Biology, 2020, 9, 310.	2.8	21
61	The Reality of Patient-Reported Outcomes of Health-Related Quality of Life in an Italian Cohort of Patients with Inflammatory Bowel Disease: Results from a Cross-Sectional Study. Journal of Clinical Medicine, 2020, 9, 2416.	2.4	16
62	Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic. Journal of Clinical Medicine, 2020, 9, 2488.	2.4	28
63	COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey. Medicina (Lithuania), 2020, 56, 407.	2.0	14
64	Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic. Archives of Pathology and Laboratory Medicine, 2020, 144, 1048-1056.	2.5	29
65	Mediterranean diet: the role of antioxidants in liver disease. , 2020, , 255-264.		0
66	Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists. Diseases (Basel, Switzerland), 2020, 8, 20.	2.5	14
67	SARS-CoV-2 and liver damage: a possible pathogenetic link. Hepatobiliary Surgery and Nutrition, 2020, 9, 322-324.	1.5	7
68	COVID-19: Perspectives on the Potential Novel Global Threat. Reviews on Recent Clinical Trials, 2020, 15, 84-86.	0.8	24
69	Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2020, 52, 374-391.	0.9	29
70	Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. Liver International, 2020, 40, 1408-1414.	3.9	22
71	Epidemiology of Coronavirus Disease Outbreak: The Italian Trends. Reviews on Recent Clinical Trials, 2020, 15, 87-92.	0.8	24
72	Gut microbiota composition changes associated with obesity: new lights from metagenomic analysis. Mìžnarodnij EndokrinologìAnij Žurnal, 2020, 16, 654-661.	0.4	1

#	Article	IF	Citations
73	The role of the COVID-19 pandemic as a risk factor for suicide: What is its impact on the public mental health state today?. Psychological Trauma: Theory, Research, Practice, and Policy, 2020, 12, S120-S122.	2.1	27
74	What Has the COVID-19 Pandemic Taught Us so Far? Addressing the Problem from a Hepatologist's Perspective. Journal of Clinical and Translational Hepatology, 2020, 8, 109-112.	1.4	33
75	The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer. Hepatoma Research, 2020, 2020, .	1.5	21
76	Barriers and Facilitators in Conducting Clinical Trials in Inflammatory Bowel Disease: A Monocentric Italian Survey. Reviews on Recent Clinical Trials, 2020, 15, 137-144.	0.8	11
77	Circadian Rhythms of Endothelial Nitric Oxide Synthase and Toll-like Receptors 2 Production in Females with Rheumatoid Arthritis Depending on NOS3 Gene Polymorphism. Reviews on Recent Clinical Trials, 2020, 15, 145-151.	0.8	6
78	Prevention of COVID-19 Infection in the Medical Population: Possible Help from Anosmia?. Reviews on Recent Clinical Trials, 2020, 15, 244-245.	0.8	4
79	Light Alcohol Drinking and the Risk of Cancer Development: A Controversial Relationship. Reviews on Recent Clinical Trials, 2020, 15, 164-177.	0.8	4
80	Critical review on the use and abuse of alcohol. When the dose makes the difference. Minerva Medica, 2020, 111, 344-353.	0.9	6
81	Mediterranean diet and probiotics supplementation to treat non-alcoholic fatty liver disease. Minerva Medica, 2020, 111, 526-528.	0.9	14
82	Combined effects of probiotic and chondroprotector during osteoarthritis in rats. Panminerva Medica, 2020, 62, 93-101.	0.8	19
83	Vitamin D3 deficiency is associated with more severe insulin resistance and metformin use in patients with type 2 diabetes. Minerva Endocrinologica, 2020, 45, 172-180.	1.8	18
84	Urotensin II receptor expression in patients with ulcerative colitis: a pilot study. Minerva Gastroenterologica E Dietologica, 2020, 66, 23-28.	2.2	3
85	Non-alcoholic fatty liver disease and primary care physicians. Minerva Gastroenterologica E Dietologica, 2020, 66, 4-5.	2.2	10
86	Hepatic steatosis indices as predictors of vitamin D3 deficiency in patients with NAFLD associated with type 2 diabetes. Clinical Diabetology, 2020, 9, 313-320.	0.6	5
87	Noninvasive assessment of liver fibrosis in chronic hepatitis C virus patients compared to liver biopsy: the experience of tertiary level hospital in Serbia. Minerva Medica, 2020, 111, 197-202.	0.9	5
88	A Framework for Patient Data Management and Analysis in Randomised Clinical Trials. , 2020, , .		0
89	Transaminases: oldies but goldies. A narrative review. Minerva Gastroenterologica E Dietologica, 2020, 66, 246-251.	2.2	21
90	Safety profile of intravenous iron in inflammatory bowel disease: an up-to-date overview. Minerva Gastroenterology, 2020, , .	0.5	1

#	Article	IF	CITATIONS
91	Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. Medicina (Lithuania), 2019, 55, 441.	2.0	12
92	A Hazelnut-Enriched Diet Modulates Oxidative Stress and Inflammation Gene Expression without Weight Gain. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-11.	4.0	20
93	Gut Microbiota and Obesity: A Role for Probiotics. Nutrients, 2019, 11, 2690.	4.1	335
94	Self-Prescribed Dietary Restrictions are Common in Inflammatory Bowel Disease Patients and Are Associated with Low Bone Mineralization. Medicina (Lithuania), 2019, 55, 507.	2.0	27
95	Diet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way. International Journal of Environmental Research and Public Health, 2019, 16, 3011.	2.6	86
96	Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease. International Journal of Environmental Research and Public Health, 2019, 16, 3134.	2.6	39
97	The Skin in Celiac Disease Patients: The Other Side of the Coin. Medicina (Lithuania), 2019, 55, 578.	2.0	28
98	Polycystic ovary syndrome: the potential role of probiotic supplementation. Minerva Medica, 2019, 110, 1-2.	0.9	1
99	Lamium Plants—A Comprehensive Review on Health Benefits and Biological Activities. Molecules, 2019, 24, 1913.	3.8	26
100	Olive oil antioxidants and non-alcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2019, 13, 739-749.	3.0	38
101	Nonalcoholic fatty liver disease in obese adolescents: the role of genetic polymorphisms. Hepatobiliary Surgery and Nutrition, 2019, 8, 179-180.	1.5	4
102	A great legal scholar of the 18th century with liver cirrhosis and septicemia. Medical Hypotheses, 2019, 127, 88-89.	1.5	0
103	Preface. Reviews on Recent Clinical Trials, 2019, 14, 3-3.	0.8	0
104	Use of Complementary and Alternative Medicine by Patients with Irritable Bowel Syndrome According to the Roma IV Criteria: A Single-Center Italian Survey. Medicina (Lithuania), 2019, 55, 46.	2.0	16
105	Probiotics supplementation in the management of hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2019, 8, 632-634.	1.5	2
106	Neuropathic diabetic foot ulcers treated with cerium dioxide nanoparticles: A case report. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 228-234.	3.6	19
107	A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 41-49.	0.9	159
108	Effect of Chondroitin Sulfate on Blood Serum Cytokine Profile during Carrageenan-induced Edema and Monoiodoacetate-induced Osteoarthritis in Rats. Reviews on Recent Clinical Trials, 2019, 14, 50-55.	0.8	15

#	Article	IF	CITATIONS
109	High Flow Through Nasal Cannula in Stable and Exacerbated Chronic Obstructive Pulmonary Disease Patients. Reviews on Recent Clinical Trials, 2019, 14, 247-260.	0.8	20
110	Older age and HDL-cholesterol as independent predictors of liver fibrosis assessed by BARD score. Minerva Medica, 2019, 110, 191-198.	0.9	22
111	Effect of probiotic on serum cytokines and matrix metalloproteinases profiles during monoiodoacetate-induced osteoarthritis in rats. Minerva Biotecnologica, 2019, 31, .	1.2	27
112	Is endocan a novel potential biomarker of liver steatosis and fibrosis?. Journal of Medical Biochemistry, 2019, 39, 363-371.	1.7	6
113	Probiotics and smectite absorbent gel formulation reduce liver stiffness, transaminase and cytokine levels in NAFLD associated with type 2 diabetes: a randomized clinical study. Clinical Diabetology, 2019, 8, 205-214.	0.6	23
114	The Complex Aura of <scp>N</scp> ikola <scp>T</scp> esla. Headache, 2018, 58, 304-305.	3.9	3
115	Resistin levels in non-alcoholic fatty liver disease pathogenesis. Journal of Translational Internal Medicine, 2018, 6, 52-53.	2.5	7
116	Potential influence of the phthalates on normal liver function and cardiometabolic risk in males. Environmental Monitoring and Assessment, 2018, 190, 17.	2.7	39
117	Efficacy and safety of new direct antiviral agents in hepatitis C virus–infected patients with diffuse large Bâ€cell nonâ€Hodgkin's lymphoma. Hepatology, 2018, 67, 48-55.	7.3	76
118	Iron deficiency anemia and hearing loss. International Journal of Pediatric Otorhinolaryngology, 2018, 113, 302.	1.0	4
119	Efficacy of Probiotics and Smectite in Rats with Non-Alcoholic Fatty Liver Disease. Annals of Hepatology, 2018, 17, 153-161.	1.5	37
120	A Systematic Review on Natural Antioxidant Properties of Resveratrol. Natural Product Communications, 2018, 13, 1934578X1801300.	0.5	21
121	Influence of FTO rs9939609 and Mediterranean diet on body composition and weight loss: a randomized clinical trial. Journal of Translational Medicine, 2018, 16, 308.	4.4	36
122	Polycystic ovary syndrome and vitamin D serum levels. Minerva Endocrinologica, 2018, 44, 82-84.	1.8	7
123	Role of genetics and metabolism in non-alcoholic fatty liver disease. Panminerva Medica, 2018, 60, 41-43.	0.8	20
124	Variability in Phelanâ€McDermid syndrome: The impact of the <i>PNPLA3</i> p.I148M polymorphism. Clinical Genetics, 2018, 94, 590-591.	2.0	11
125	Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease. Pharmaceuticals, 2018, 11, 104.	3.8	60
126	Rosmarinic Acid as Potential Anti-Inflammatory Agent. Reviews on Recent Clinical Trials, 2018, 13, 240-242.	0.8	49

#	Article	IF	CITATIONS
127	The role of nanotechnology in food safety. Minerva Biotechnology and Biomolecular Research, 2018, 30, .	0.5	3
128	Mediterranean diet in liver steatosis: the role of polyphenols. Minerva Gastroenterology, 2018, 64, 97-99.	0.5	4
129	Milk thistle (<scp><i>Silybum marianum</i></scp>): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytotherapy Research, 2018, 32, 2202-2213.	5.8	274
130	Health benefits of Mediterranean diet in nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2018, 12, 873-881.	3.0	44
131	Preface. Reviews on Recent Clinical Trials, 2018, 13, 2.	0.8	0
132	Basics in Endoscopic Ultrasound Part 2: EUS-guided Sampling and Therapeutic Applications. Reviews on Recent Clinical Trials, 2018, 13, 97-104.	0.8	2
133	The Emerging Role of Complement C3 as A Biomarker of Insulin Resistance and Cardiometabolic Diseases: Preclinical and Clinical Evidence. Reviews on Recent Clinical Trials, 2018, 13, 61-68.	0.8	23
134	Serum Complement C3 and Type 2 Diabetes in Rheumatoid Arthritis: A Case-Control Study. Reviews on Recent Clinical Trials, 2018, 13, 215-221.	0.8	4
135	Vitamin D supplementation in patients with alcoholic liver cirrhosis: a prospective study. Minerva Medica, 2018, 109, 352-357.	0.9	25
136	Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study. Minerva Medica, 2018, 109, 418-428.	0.9	82
137	Hepatitis C virus-induced hepatocellular carcinoma: a narrative review. Panminerva Medica, 2018, 60, 185-191.	0.8	34
138	Basics in Endoscopic Ultrasound Part 1: Diagnostic Indications and Tissue Sampling. Reviews on Recent Clinical Trials, 2018, 13, 27-36.	0.8	3
139	The relationship between the vitamin serum 25(OH)D and the B12 concentrations in obese women. Minerva Medica, 2018, 109, 79-87.	0.9	6
140	Is possible to detect nonalcoholic fatty liver disease by a new index including single nucleotide polymorphisms (SNPs)?. Annals of Translational Medicine, 2018, 6, 366-366.	1.7	0
141	Gut microbiota changes and chronic hepatitis C virus infection. Expert Review of Gastroenterology and Hepatology, 2017, 11, 813-819.	3.0	83
142	Alcohol consumption survey in an outpatient center of gastroenterology in southern Italy. Digestive and Liver Disease, 2017, 49, e237.	0.9	0
143	The impact of genetic polymorphisms on liver diseases. European Journal of Gastroenterology and Hepatology, 2017, 29, 1102-1103.	1.6	5
144	Complement C3 and fatty liver disease in Rheumatoid arthritis patients: a cross-sectional study. European Journal of Clinical Investigation, 2017, 47, 728-735.	3.4	26

#	Article	IF	CITATIONS
145	Adiponectin serum level changes and its dynamic relationship with hepatitis C during viral clearance. Virulence, 2017, 8, 1069-1071.	4.4	1
146	Polyphenols treatment in patients with nonalcoholic fatty liver disease. Journal of Translational Internal Medicine, 2017, 5, 144-147.	2.5	35
147	The influence of phthalates and bisphenol A on the obesity development and glucose metabolism disorders. Endocrine, 2017, 55, 666-681.	2.3	144
148	The fever of Tommaso Campanella. Internal and Emergency Medicine, 2017, 12, 1337-1338.	2.0	1
149	Influence of Famine in Women with Non-Alcoholic Fatty Liver Disease. Annals of Hepatology, 2017, 16, 826-827.	1.5	3
150	Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients, 2017, 9, 870.	4.1	102
151	Adiponectin in hepatology. Minerva Biotechnology and Biomolecular Research, 2017, 30, .	0.5	3
152	New serum markers for detection of early hepatocellular carcinoma. Panminerva Medica, 2017, 59, 281-282.	0.8	7
153	Silymarin: An option to treat non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2017, 23, 8437-8438.	3.3	18
154	Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2017, 23, 3150.	3.3	99
155	Genetic and Epigenetic Profile of Patients With Alcoholic Liver Disease. Annals of Hepatology, 2017, 16, 490-500.	1.5	32
156	Meet Our Editor. Reviews on Recent Clinical Trials, 2017, 12, 1-1.	0.8	1
157	Preface. Reviews on Recent Clinical Trials, 2017, 12, 2-2.	0.8	0
158	Autoimmune thyroid diseases in patients with chronic hepatitis C treated by pegylated interferon-alpha and ribavirin: A prospective study. Srpski Arhiv Za Celokupno Lekarstvo, 2017, 145, 43-48.	0.2	0
159	Editorial (Thematic Issue: Alcoholic Liver Disease: From Bench to Bedside). Reviews on Recent Clinical Trials, 2016, 11, 158-158.	0.8	0
160	Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2016, 22, 7006.	3.3	133
161	Non-cirrhotic Portal Hypertension Associated with Didanosine and Streptococcus agalactiae Infection: A Case Report. Reviews on Recent Clinical Trials, 2016, 11, 152-155.	0.8	2
162	Pharmacotherapy of alcoholic liver disease in clinical practice. International Journal of Clinical Practice, 2016, 70, 119-131.	1.7	24

#	Article	IF	CITATIONS
163	Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy, 2016, 17, 1395-1402.	1.8	10
164	Body Composition and Non-alcoholic Fatty Liver Disease. Journal of Lifestyle Medicine, 2016, 6, 47-48.	0.8	4
165	Prevention of NAFLD development in rats with obesity via the improvement of pro/antioxidant state by cerium dioxide nanoparticles. Medicine and Pharmacy Reports, 2016, 89, 229-235.	0.4	14
166	Alcoholic Liver Disease and Hepatitis C Chronic Infection. Reviews on Recent Clinical Trials, 2016, 11, 201-207.	0.8	7
167	Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment. Reviews on Recent Clinical Trials, 2016, 11, 159-166.	0.8	30
168	The Role of Liver Biopsy to Assess Alcoholic Liver Disease. Reviews on Recent Clinical Trials, 2016, 11, 175-179.	0.8	11
169	May Patients with Alcohol Liver Disease Benefit from Herbal Medicines?. Reviews on Recent Clinical Trials, 2016, 11, 227-237.	0.8	4
170	Laboratory Tests for Diagnosis of Alcoholic Liver Disease. Reviews on Recent Clinical Trials, 2016, 11, 180-184.	0.8	2
171	Gut Microbiota and Alcoholic Liver Disease. Reviews on Recent Clinical Trials, 2016, 11, 213-219.	0.8	26
172	Epidemiology and Natural History of Alcoholic Liver Disease. Reviews on Recent Clinical Trials, 2016, 11, 167-174.	0.8	52
173	The Effect of Alcohol on Gastrointestinal Motility. Reviews on Recent Clinical Trials, 2016, 11, 191-195.	0.8	12
174	Chronic Hepatitis C and Alcohol Abuse: The Single Center Experience of Novi Sad - Serbia. Reviews on Recent Clinical Trials, 2016, 11, 208-212.	0.8	3
175	Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy―Experience in Southern Italy. Reviews on Recent Clinical Trials, 2016, 11, 306-316.	0.8	4
176	Editorial (Thematic Issue: Non-Alcoholic Fatty Liver Disease: Today and Tomorrow). Reviews on Recent Clinical Trials, 2015, 9, 125-125.	0.8	2
177	Lifestyle changes associated with a new antioxidant formulation in non-alcoholic fatty liver disease: a case series. Annals of Hepatology, 2015, 14, 121-126.	1.5	4
178	HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?. Annals of Hepatology, 2015, 14, 325-332.	1,5	3
179	Non-alcoholic fatty liver disease and beneficial effects of dietary supplements. World Journal of Hepatology, 2015, 7, 1723.	2.0	6
180	Non-alcoholic fatty liver disease severity, central fat mass and adinopectin: a close relationship. Medicine and Pharmacy Reports, 2015, 88, 489-493.	0.4	14

#	Article	IF	Citations
181	Risk factors for accelerated atherosclerosis in young women with hyperprolactinemia. Medical Hypotheses, 2015, 84, 321-326.	1.5	21
182	Estimation of inÂvivo and inÂvitro exposure to bisphenol A as food contaminant. Food and Chemical Toxicology, 2015, 83, 268-274.	3.6	25
183	Effects of Mediterranean diet supplemented with silybin–vitamin E–phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2015, 9, 519-527.	3.0	72
184	Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. Journal of Hepatology, 2015, 63, 1449-1458.	3.7	84
185	Enhanced Expression of Indoleamine 2,3â€Dioxygenase in <i>Helicobacter pylori</i> â€Infected Human Gastric Mucosa Modulates Th1/Th2 Pathway and Interleukin 17 Production. Helicobacter, 2015, 20, 41-48.	3.5	26
186	The Role of Liver Biopsy to Assess Non-Alcoholic Fatty Liver Disease. Reviews on Recent Clinical Trials, 2015, 9, 159-169.	0.8	35
187	Role of Adipokines and Cytokines in Non-alcoholic Fatty Liver Disease. Reviews on Recent Clinical Trials, 2015, 9, 134-140.	0.8	76
188	Phytotherapy and NAFLD - from Goals and Challenges to Clinical Practice. Reviews on Recent Clinical Trials, 2015, 9, 195-203.	0.8	24
189	Non Alcoholic Fatty Liver: Epidemiology and Natural History. Reviews on Recent Clinical Trials, 2015, 9, 126-133.	0.8	215
190	Role of endoscopy in management of gastrointestinal complications of portal hypertension. World Journal of Gastrointestinal Endoscopy, 2015, 7, 1.	1.2	9
191	Adiponectin serum level in chronic hepatitis C infection and therapeutic profile. World Journal of Hepatology, 2015, 7, 44.	2.0	16
192	Lifestyle changes associated with a new antioxidant formulation in non-alcoholic fatty liver disease: a case series. Annals of Hepatology, 2015, 14, 121-6.	1.5	2
193	Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. Expert Review of Gastroenterology and Hepatology, 2014, 8, 343-349.	3.0	36
194	C677T gene polymorphism of MTHFR and metabolic syndrome: response to dietary intervention. Journal of Translational Medicine, 2014, 12, 329.	4.4	21
195	Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World Journal of Gastroenterology, 2014, 20, 15233.	3.3	57
196	Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World Journal of Gastroenterology, 2014, 20, 16831.	3.3	90
197	Pharmacotherapy of acute alcoholic hepatitis in clinical practice. World Journal of Gastroenterology, 2014, 20, 2159.	3.3	12
198	Prevalence of Peripheral Artery Disease by Abnormal Ankle-Brachial Index in Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 62, 2255-2256.	2.8	49

#	Article	IF	CITATIONS
199	Liver Transplantation in Alcoholic Patients: Impact of an Alcohol Addiction Unit Within a Liver Transplant Center. Alcoholism: Clinical and Experimental Research, 2013, 37, 1601-1608.	2.4	156
200	Milk thistle to treat non-alcoholic fatty liver disease: dream or reality?. Expert Review of Gastroenterology and Hepatology, 2013, 7, 677-679.	3.0	25
201	Dietary Intervention in Non-Alcoholic Fatty Liver Disease. Journal of the Academy of Nutrition and Dietetics, 2013, 113, 211.	0.8	4
202	Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. Medical Hypotheses, 2013, 81, 913-915.	1.5	18
203	A pathogenetic link between non-alcoholic fatty liver disease and celiac disease. Endocrine, 2013, 43, 65-67.	2.3	31
204	Type 2 diabetes mellitus in chronic hepatitis C virus infection: risk factor or consequence?. Expert Review of Gastroenterology and Hepatology, 2013, 7, 295-297.	3.0	2
205	Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, S55-S60.	0.4	12
206	New Therapeutic Potentials of Milk Thistle (<i>Silybum marianum</i>). Natural Product Communications, 2013, 8, 1934578X1300801.	0.5	35
207	Severe hepatitis induced by cyproterone acetate: role of corticosteroids. A case report. Annals of Hepatology, 2013, 12, 152-155.	1.5	10
208	Probiotics in non-alcoholic fatty liver disease: which and when. Annals of Hepatology, 2013, 12, 357-363.	1.5	32
209	Hepatitis C virus genotypes in north eastern Algeria: A retrospective study. World Journal of Hepatology, 2013, 5, 393.	2.0	22
210	Probiotics in non-alcoholic fatty liver disease: which and when. Annals of Hepatology, 2013, 12, 357-63.	1.5	13
211	New therapeutic potentials of milk thistle (Silybum marianum). Natural Product Communications, 2013, 8, 1801-10.	0.5	35
212	Bone Mineralization in Celiac Disease. Gastroenterology Research and Practice, 2012, 2012, 1-9.	1.5	55
213	High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease. European Journal of Internal Medicine, 2012, 23, 273-277.	2.2	12
214	Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin. Endocrine, 2012, 42, 754-755.	2.3	17
215	Transient elastography in non-alcoholic fatty liver disease. Annals of Hepatology, 2012, 11, 172-178.	1.5	48
216	Helicobacter species and liver disease. Journal of Gastroenterology, 2012, 47, 723-723.	5.1	0

#	Article	IF	CITATIONS
217	No evidence of circulating autoantibodies against osteoprotegerin in patients with celiac disease. World Journal of Gastroenterology, 2012, 18, 1622.	3.3	32
218	Transient elastography in non-alcoholic fatty liver disease. Annals of Hepatology, 2012, 11, 172-8.	1.5	14
219	Chronic hepatitis C infection and insulin resistance: two best friends. Expert Review of Anti-Infective Therapy, 2011, 9, 555-558.	4.4	10
220	Role of silymarin to treat fibrosis development in nonâ€alcoholic fatty liver disease. Hepatology Research, 2011, 41, 668-668.	3.4	3
221	Insulin resistance increases risk of carpal tunnel syndrome: a caseâ€control study. Journal of the Peripheral Nervous System, 2011, 16, 186-190.	3.1	25
222	Adiponectin levels in nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2011, 60, e3.	3.4	3
223	" and Suddenly a Tree!― International Journal of Surgical Pathology, 2011, 19, 776-776.	0.8	1
224	The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C. Hepatitis Monthly, 2011, 11, 240-6.	0.2	10
225	Shortâ€term Therapy with Celecoxib and Lansoprazole Modulates Th1/ Th2 Immune Response in Human Gastric Mucosa. Helicobacter, 2010, 15, 449-459.	3.5	11
226	Behçet's disease and celiac disease: a rare association or a possible link?. Rheumatology International, 2010, 30, 1405-1405.	3.0	3
227	Metformin: A Therapeutic Option for Treating Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2010, 55, 2121-2121.	2.3	0
228	Brain hypoperfusion and neurological symptoms in celiac disease. Movement Disorders, 2010, 25, 799-800.	3.9	7
229	Milk thistle in liver diseases: past, present, future. Phytotherapy Research, 2010, 24, 1423-1432.	5.8	420
230	Non-alcoholic fatty liver disease and pharmacological options. International Journal of Clinical Practice, 2010, 64, 1583-1583.	1.7	0
231	Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. International Journal of Obesity, 2010, 34, 1255-1264.	3.4	111
232	Nervous system in the gluten syndrome: A close relationship. Medical Hypotheses, 2010, 74, 204-205.	1.5	4
233	Garlic: Empiricism or Science?. Natural Product Communications, 2009, 4, 1934578X0900401.	0.5	46
234	Phytotherapeutic approach to alcohol dependence: New old way?. Phytomedicine, 2009, 16, 638-644.	5. 3	17

#	Article	IF	Citations
235	Celiac disease: from gluten to skin. Expert Review of Clinical Immunology, 2009, 5, 789-800.	3.0	12
236	Garlic: empiricism or science?. Natural Product Communications, 2009, 4, 1785-96.	0.5	39
237	Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology, 2008, 48, 871-877.	7.3	552
238	Elastography assessment in patients with chronic HCV infection. International Journal of Clinical Practice, 2008, 62, 1108-1112.	1.7	13
239	State and trait anxiety and depression in patients affected by gastrointestinal diseases: psychometric evaluation of 1641 patients referred to an internal medicine outpatient setting. International Journal of Clinical Practice, 2008, 62, 1063-1069.	1.7	120
240	Subclinical Neurological Abnormalities and Gluten-Free Diet. Journal of the American Dietetic Association, 2008, 108, 1995.	1.1	2
241	Probiotics: Which and When?. Digestive Diseases, 2008, 26, 175-182.	1.9	27
242	Acute alcohol intoxication. European Journal of Internal Medicine, 2008, 19, 561-567.	2.2	270
243	Metabolic and Nutritional Features in Adult Celiac Patients. Digestive Diseases, 2008, 26, 128-133.	1.9	32
244	Intestinal Malabsorption and Skin Diseases. Digestive Diseases, 2008, 26, 167-174.	1.9	14
245	Affective and Psychiatric Disorders in Celiac Disease. Digestive Diseases, 2008, 26, 140-148.	1.9	37
246	Subclinical Neurological Abnormalities in Patients With Celiac Disease: Are They Associated by Brain Hypoperfusion?. Journal of Pediatric Gastroenterology and Nutrition, 2008, 46, 470-470.	1.8	1
247	Superior vena cava thrombosis treated by angioplasty and stenting in a cirrhotic patient with peritoneovenous shunt. Annals of Thoracic and Cardiovascular Surgery, 2008, 14, 60-2.	0.8	4
248	Neuroendocrine and Psychological Assessment in a Guinness 10 Days Scuba Dive. International Journal of Sports Medicine, 2007, 28, 848-852.	1.7	1
249	Penicillamine-Related Lichenoid Dermatitis and Utility of Zinc Acetate in a Wilson Disease Patient with Hepatic Presentation, Anxiety and Spect Abnormalities. International Journal of Immunopathology and Pharmacology, 2007, 20, 185-190.	2.1	4
250	Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: An open randomised comparative study. European Neuropsychopharmacology, 2007, 17, 781-789.	0.7	53
251	Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet, The, 2007, 370, 1915-1922.	13.7	611
252	Elastography in Hepatology. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 839-842.	1.7	28

#	Article	IF	CITATIONS
253	Celiac disease and skin: Psoriasis association. World Journal of Gastroenterology, 2007, 13, 2138.	3.3	12
254	Analysis of the T1288R Mutation of the Wilson Disease ATP7B Gene in Four Generations of a Family: Possible Genotype-Phenotype Correlation with Hepatic Onset. Digestive Diseases and Sciences, 2007, 52, 2570-2575.	2.3	11
255	Primary renal angiosarcoma: A rare malignancy. A case report and review of the literatureâ ⁻ †. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 307-312.	1.6	48
256	Complementary medicine for alcohol dependence in Italian services: A mail questionnaire. Complementary Therapies in Clinical Practice, 2006, 12, 216-221.	1.7	4
257	Baclofen in the Treatment of Alcohol Withdrawal Syndrome: A Comparative Study vs Diazepam. American Journal of Medicine, 2006, 119, 276.e13-276.e18.	1.5	173
258	Cutaneous manifestations in celiac disease. World Journal of Gastroenterology, 2006, 12, 843.	3.3	77
259	Relationship Between Ghrelin Levels, Alcohol Craving, and Nutritional Status in Current Alcoholic Patients. Alcoholism: Clinical and Experimental Research, 2006, 30, 1933-1937.	2.4	154
260	A New Mutation of Wilson's Disease P-Type ATPase Gene in a Patient with Cirrhosis and Coombs-Positive Hemolytic Anemia. Digestive Diseases and Sciences, 2006, 51, 34-38.	2.3	8
261	Marked Decrease of Serum Ca 125 Levels After Denver Shunt Placement in a Patient With Cirrhosis and Refractory Ascites. Digestive Diseases and Sciences, 2006, 51, 1644-1646.	2.3	2
262	Genotype–phenotype correlation of the Wilson diseaseATP7B gene. American Journal of Medical Genetics, Part A, 2006, 140A, 933-933.	1.2	14
263	Suppression of Craving for \hat{l}^3 -Hydroxybutyric Acid by Naltrexone Administration. Clinical Neuropharmacology, 2005, 28, 87-89.	0.7	11
264	CELIAC DISEASE AND SKIN DISORDERS. Pediatric Dermatology, 2005, 22, 376-377.	0.9	2
265	Association between psoriasis and coeliac disease. British Journal of Dermatology, 2005, 152, 1393-1394.	1.5	11
266	Tolerance to baclofen?s sedative effect in alcohol-addicted patients: no dissipation after a period of abstinence. Psychopharmacology, 2005, 178, 351-352.	3.1	7
267	Psychological Support Counseling: A New Strategy to Increase Gluten-Free Diet Compliance in Celiac Patients. American Journal of Gastroenterology, 2005, 100, 1424-1425.	0.4	2
268	How Many Cravings? Pharmacological Aspects of Craving Treatment in Alcohol Addiction: A Review. Neuropsychobiology, 2005, 51, 59-66.	1.9	117
269	Gamma hydroxybutyrric acid (GHB) withdrawal does not occur at therapeutic dosage. Drug and Alcohol Dependence, 2005, 77, 209.	3.2	12
270	Neurobiochemical and clinical aspects of craving in alcohol addiction: A review. Addictive Behaviors, 2005, 30, 1209-1224.	3.0	147

#	Article	IF	CITATIONS
271	Editor's Correspondence. Archives of Internal Medicine, 2005, 165, 586.	3.8	1
272	Baclofen: clinical data., 2005,, 171-180.		1
273	Neurologic Disorders in Patients With Celiac Disease: Are They Mediated by Brain Perfusion Changes?. Pediatrics, 2004, 114, 1734-1734.	2.1	3
274	Gluten-related cerebral hypoperfusion and neurologic disorders in coeliac patients. Alimentary Pharmacology and Therapeutics, 2004, 20, 821-822.	3.7	2
275	Psychological support counselling improves glutenâ€free diet compliance in coeliac patients with affective disorders. Alimentary Pharmacology and Therapeutics, 2004, 20, 777-782.	3.7	90
276	Rapid Regression of Psoriasis in a Coeliac Patient after Gluten-Free Diet. Digestion, 2003, 68, 9-12.	2.3	57
277	Suppression of Alcohol Delirium Tremens by Baclofen Administration: A Case Report. Clinical Neuropharmacology, 2003, 26, 258-262.	0.7	56
278	Biliary acids as promoters of colon carcinogenesis: a narrative review. Digestive Medicine Research, 0, 4, 33-33.	0.2	1
279	Beneficial effects of coffee in non-alcoholic fatty liver disease: a narrative review. Hepatoma Research, 0, 2020, .	1.5	4